Membranous Nephropathy Market Size

Global Membranous Nephropathy Market Overview

Membranous Nephropathy Market Size was valued at USD 0.33 Billion in 2023. The Global Membranous Nephropathy industry is projected to grow from USD 0.35 Billion in 2024 to USD 0.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.84% during the forecast period (2024 - 2032). The market of membranous nephropathy is expected to grow at an overall rate owing to the increasing number of kidney diseases and frail geriatric population across the globe. The impact of COVID-19 on the market of membranous nephropathy has already started to be felt. The disease outbreak has led to lockdowns, slowing the growth of many markets. These are the key market drivers enhancing market growth.

Membranous Nephropathy Market Trends

• Increased prevalence of kidney disease boosting the market growth

The major market drivers of the membranous nephropathy are the increasing prevalence of kidney diseases, the rising geriatric population resulting in rising patient numbers, rising hepatitis infections, and an increasing number of young people tending towards a sedentary lifestyle. Additionally, government funding, rising demand for novel treatments, and market players offering advanced products will likely drive the market.

According to United Nations statistics, in 2017, there were more than 962 million people in the world aged 60 and over. The United Nations also estimates that older people could reach 425 million by 2050. Additionally, approximately 71 million people worldwide are infected with hepatitis C, according to the World Health Organization. A rising aging population and rising hepatitis cases are likely to drive the growth of the membranous nephropathy market. Factors hindering the market's growth are the need for more awareness about the treatment.

The increasing geriatric population in the U.S. and the target population considered to be membranous nephropathy are likely to drive the market growth of the membranous nephropathy. Complications associated with kidney transplantation and the chances of recurrence of membranous nephropathy in patients may hamper the market for membranous nephropathy for kidney transplantation. Rising healthcare expenditure may lead to technological advancements and an increase in treatment options, which may act as an opportunity for the market growth of the membranous nephropathy. A lack of skilled professionals leads to correct diagnosis and treatment, making the process more convenient and convenient. If left untreated can lead to complications for patients, which is a challenging factor for the market growth of the membranous nephropathy. Therefore, the Membranous Nephropathy market CAGR has been increasing ly in recent years. These are essential factors driving the market revenue growth of the Membranous Nephropathy.

Membranous Nephropathy Market Segment Insights

Membranous Nephropathy Product Type Insights

Based on product type, the market segmentation of Membranous Nephropathy includes primary and secondary. The primary segment held the majority share in 2022 of the Membranous Nephropathy market revenue. The primary membranous nephropathy segment will dominate the market by approximately 80% of cases are restricted, i.e., patients with membranous nephropathy associated with other diseases.

Membranous Nephropathy Type Insights

Based on type, the market segments of Membranous Nephropathy includes conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy. The conservative therapy segment held the majority share in 2022 of the Membranous Nephropathy market revenue. Conservative treatment is a type of medical treatment defined as avoiding invasive measures such as surgery or other invasive procedures, usually aimed at preserving function or body parts.

Figure 1 Membranous Nephropathy Market by Type, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Membranous Nephropathy Material Type Insights

Based on material type, the Membranous Nephropathy market segmentation includes Urine Tests (Urinalysis), Blood Tests, Glomerular Filtration Rate Tests, and Antinuclear Antibody Tests. The urine test (Urinalysis) segment held the majority share 2022 of the market revenue for Membranous Nephropathy. Urinary sediment is usually nephrotic, with fat oval bodies and fatty casts; however, in mild cases, urinalysis may reveal proteinuria with no forming components in the sediment. Standard blood and urine tests confirm the diagnosis of nephrotic syndrome, its associated abnormalities, and the level of kidney function.

Membranous Nephropathy Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Membranous Nephropathy market accounted for USD 0.1 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Increasing hepatitis affecting the population along with the increasing geriatric population is likely to drive the market. Additionally, rising healthcare spending, demand for technologically advanced treatments and products, and increasing government support are likely to boost North American membranous nephropathy market growth.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 MEMBRANOUS NEPHROPATHY MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Membranous Nephropathy market accounts for the second-largest market share. Europe is the second largest market, with a healthy share in the market of membranous nephropathy. The European market is expected to grow at a healthy CAGR over the forecast period owing to the availability of newer and advanced treatment facilities, the rise in skilled medical professionals, and the growing demand for better healthcare options. Moreover, several recalls suggest that the increasing geriatric population and a rising sedentary lifestyle drive the market growth of the membranous nephropathy. Further, the Germany market of Membranous Nephropathy held the largest market share, and the U.K. market of Membranous Nephropathy was the fastest-growing market in the European Region.

The Asia-Pacific Membranous Nephropathy Market is expected to grow at the fastest CAGR from 2024 to 2032. The increasing prevalence of chronic diseases and infections is the primary driver for market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. Rising awareness regarding health and the availability of new treatment methods drive the market in this Region. Rising healthcare expenditure and a rise in the standard of living are driving the market growth of the membranous nephropathy in the Asia Pacific region. Moreover, the China market of Membranous Nephropathy held the largest market share, and the India market of Membranous Nephropathy was the fastest-growing market in the Asia-Pacific region.

Membranous Nephropathy Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the market of Membranous Nephropathy grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Membranous Nephropathy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Membranous Nephropathy industry to benefit clients and expand the market sector. The Membranous Nephropathy industry has provided medicine with some of the most significant benefits in recent years. In the Membranous Nephropathy markets, major players such as Abbvie, Inc., Allergan Plc., Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., and others are working on expanding the market demand by investing in research and development activities.

AbbVie is an American-listed pharmaceutical company established in 2013. It originated from the spin-off company of Abbott Laboratories. It is one of the largest pharmaceutical companies in the world, and its revenue often ranks among the top three in the world. In March 2022, Abbvie announced it would acquire Belgium-based Syndesi Therapeutics and its portfolio of novel modulators of synaptophysin 2A and lead compound SDI-118 for up to $1 billion. In October, AbbVie announced that they would acquire UK-based biotechnology company DJS Antibodies for $225 million, giving them access to an experimental drug for aggressive lung disease and developing particular antibody drugs Technology.

Also, Allergan plc is a US-Irish registered pharmaceutical company that acquires, develops, manufactures, and sells branded pharmaceuticals and medical devices in aesthetic medicine, eye care, central nervous system, and gastroenterology. The company is the manufacturer of Botox. On May 8, 2020, AbbVie completed the acquisition of Allergan.

Key Companies in the market of Membranous Nephropathy include

• Abbvie, Inc.


• Allergan Plc.,


• Amgen Inc.


• AstraZeneca Plc


• Hoffmann-La Roche Ltd


• FibroGen, Pfizer Inc., among others

Membranous Nephropathy Industry Developments

November 2023NephroGenex announces positive results from Phase 2 clinical trial of NXP001 for the treatment of membranous nephropathy (MN). NXP001 is a monoclonal antibody that targets CD38, a protein that is overexpressed in MN patients. The trial showed that NXP001 was safe and effective in reducing proteinuria, a hallmark of MN.Novartis receives FDA breakthrough therapy designation for its investigational drug, iptacopan, for the treatment of MN. Iptacopan is an orally administered small molecule inhibitor of complement factor 5a (C5a), a protein that plays a role in inflammation. Novartis is currently conducting a Phase 3 clinical trial of iptacopan in MN patients.

October 2023AstraZeneca and Silence Therapeutics announce collaboration to develop siRNA therapies for MN. AstraZeneca and Silence Therapeutics will develop and commercialize siRNA therapies that target genes that are involved in the development of MN.Boehringer Ingelheim and Eli Lilly announce new clinical trials for their oral SGLT2 inhibitor, empagliflozin, for the treatment of MN. Empagliflozin is a blood sugar-lowering drug that has also been shown to have anti-inflammatory effects. Boehringer Ingelheim and Eli Lilly are conducting two Phase 3 clinical trials of empagliflozin in MN patients.

September 2023Fresenius Medical Care launches new global initiative to raise awareness of MN and improve access to care. The initiative, called the "Fresenius Medical Care Kidney Disease Program," will provide educational resources and support services to MN patients and their families.DaVita Kidney Care partners with Verily to develop new digital health tools for people with MN. DaVita Kidney Care and Verily will develop new digital health tools that will help MN patients to track their symptoms, manage their medications, and stay connected with their healthcare team.

August 2023Otsuka Pharmaceutical and Bristol Myers Squibb announce new clinical trials for their oral HIF-2α inhibitor, avapritinib, for the treatment of MN. Avapritinib is a drug that targets HIF-2α, a protein that is involved in inflammation and angiogenesis. Otsuka Pharmaceutical and Bristol Myers Squibb are conducting two Phase 3 clinical trials of avapritinib in MN patients.

July 2023AstraZeneca and Silence Therapeutics announce new preclinical data on their siRNA therapy for MN. The preclinical data showed that the siRNA therapy was effective in reducing proteinuria and improving kidney function in MN mice.Boehringer Ingelheim and Eli Lilly announce positive results from Phase 2 clinical trial of empagliflozin for the treatment of MN. The trial showed that empagliflozin was safe and effective in reducing proteinuria in MN patients.

Membranous Nephropathy Market Segmentation

Membranous Nephropathy Product Type Outlook

• Fingertip


• Consists of Handheld


• other

Membranous Nephropathy Type Outlook

• Fingertip


• Consists of Handheld


• other

Membranous Nephropathy Material Type Outlook

• Medical Amenities


• Hospitals


• Respiratory & Cardiac Centers


• Homecare

Membranous Nephropathy Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America